gaia-platform
(2)
Suchul Jang
He spent a decade engineering tiny vesicles to smuggle drugs where they were needed. Now he is running the American arm of a Korean biotech that wants the brain to clean up after itself - quietly, without the inflammation that has shadowed Alzheimer's drugs for years.
Illimis Therapeutics
Illimis Therapeutics is a Seoul-based biotechnology company developing protein-based medicines for central nervous system and immune diseases. Its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform builds bispecific fusion proteins that engage the body's TAM receptors to clear misfolded proteins such as amyloid-beta through phagocytosis without triggering the inflammation and ARIA side effects associated with existing antibody drugs. Founded in 2021, the company raised a $42 million Series B in July 2025 and is advancing a lead Alzheimer's candidate, ILM01, toward an IND by the end of 2027.